Achillion Pharma beats by $0.01 :
- Reports Q1 (Mar) loss of $0.15 per share, $0.01 better than the Capital IQ Consensus of ($0.16).
- PNH (Paroxysmal Nocturnal Hemoglobinuria)
- Enrollment of patients into this trial in ongoing. Two patients have completed 28 days of dosing and each continues to receive longer term treatment, for up to an additional two months with ACH-4471, under the protocol. Interim results are anticipated during the second quarter.
- C3G (C3 Glomerulopathy)
- As ACH-4471 has been shown in vitro to inhibit alternative pathway activity, potentially decreasing the formation of C3 protein fragments, the company plans to initiate a phase 2 study of ACH-4471 in C3G patients during the second half of 2017.
- OMEGA-1 Phase 2b
- Results from this trial are anticipated during the second half of 2017.
- Cash, cash equivalents, marketable securities, and interest receivable as of March 31, 2017 were $386.6 million.
No comments:
Post a Comment